[Application and research progress of anti-IL-4α monoclonal antibody dupilumab in the treatment of type 2 asthma].

Abstract

According to the immune-inflammatory mediated characteristics of patients, asthma can be divided into two phenotypes: type 2 asthma and non-type 2 asthma. The onset of symptoms and pathophysiological changes in type 2 asthma are closely related to type 2 cytokines such as IL-4, IL-13 and IL-5. Dupilumab is a fully humanized monoclonal antibody that binds IL-4Rα and inhibits the signaling of both IL-4 and IL-13, to block type 2 inflammatory response and significantly improve asthma symptoms, reduce acute exacerbations, reduce oral corticosteroid dosage, and improve quality of life. This review summarizes the key medical evidence and recommendations from guidelines and consensus on the use of dupilumab in the treatment of type 2 asthma in recent years, and provides a reference for clinical physicians in China to use it rationally.